Effect of XXXX , @entity205 , and both in combination in a murine corneal graft rejection model.

@entity137 @entity870 @entity205 @entity2098 @entity618 @entity35
AIMS: To compare the effectiveness of @entity618 ( @entity2098 ), @entity205 ( @entity870 ), and both in combination, in preventing rejection following corneal transplantations. METHODS: @entity35 of the inbred strains Brown Norway and Lewis were used as donors and recipients respectively. @entity2098 was administered orally in both monotherapy and combination therapy for 14 days in a dosage of 40 mg/kg body weight, and @entity870 was administered, likewise for 14 days, in an intramuscular dosage of 10 mg/kg body weight. The transplants were examined every third day by slit lamp microscopy. Every transplant was subjected to histological or immunohistological evaluation. RESULTS: The average transplant survival rate in the allogenic strain combination was 7.9 days (SEM 1.1). Monotherapy with @entity2098 led to a statistically significant prolongation of transplant survival to 11.6 days (SEM 0.9, p < 0.05). Monotherapy with @entity870 delayed transplant rejection statistically significantly longer than @entity2098 (21 days, 0.0, p < 0.05). The combination therapy with @entity870 and @entity2098 was statistically significantly superior to the monotherapy with @entity2098 (22.3 days, 0.5, p < 0.05). The combination therapy prolonged transplant survival compared with the @entity870 monotherapy, albeit not to a statistically significant extent. CONCLUSIONS: In this study we were able to prove the immunosuppressive effect of oral @entity2098 on acute rejection following corneal transplantation. Double drug therapy with @entity870 and @entity2098 conferred a marginal benefit without a higher incidence of complications related to @entity137 or overimmunosuppression.
